Loading
NASDAQHealthcareBiotechnology
Latest quote
$1.02
−$0.045 · -4.23%
PDS Biotechnology Corporation is a clinical-stage biopharmaceutical firm dedicated to advancing innovative, multi-functional immunotherapies to combat cancer. Its primary drug candidate, PDS0101 (HPV16), is currently undergoing Phase II clinical trials, positioned as an initial treatment option for recurrent or metastatic head and neck cancer, human papillomavirus (HPV)-associated malignancies, and cervical cancer. The company's developmental pipeline further includes several preclinical product candidates. These comprise PDS0102, utilizing T-cell receptor gamma alternate reading frame protein (TARP) for prostate and breast cancers; PDS0103 (MUC-1) targeting ovarian, colorectal, lung, and breast cancers; and PDS0104, which incorporates Tyrosinase-related protein 2 for the treatment of melanoma. Beyond oncology, PDS Biotechnology is also engaged in developing treatments for infectious diseases, with candidates such as PDS0201 for tuberculosis, PDS0202 as an investigational influenza vaccine, and PDS0203, a vaccine aimed at preventing COVID-19. The company has established strategic partnerships and licensing agreements with notable entities including the National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. PDS Biotechnology Corporation was founded in 2005 and is headquartered in Florham Park, New Jersey.
Previous close
$1.02
−$0.045 · -4.23%
Pre-market
$1.0298
+$0.0098 · +0.96%
Oct 9, 9:08 AM ET
Regular session · ET · Market data may be delayed.
PDS Biotechnology Corporation is a clinical-stage biopharmaceutical firm dedicated to advancing innovative, multi-functional immunotherapies to combat cancer. Its primary drug candidate, PDS0101 (HPV16), is currently undergoing Phase II clinical trials, positioned as an initial treatment option for recurrent or metastatic head and neck cancer, human papillomavirus (HPV)-associated malignancies, and cervical cancer. The company's developmental pipeline further includes several preclinical product candidates. These comprise PDS0102, utilizing T-cell receptor gamma alternate reading frame protein (TARP) for prostate and breast cancers; PDS0103 (MUC-1) targeting ovarian, colorectal, lung, and breast cancers; and PDS0104, which incorporates Tyrosinase-related protein 2 for the treatment of melanoma. Beyond oncology, PDS Biotechnology is also engaged in developing treatments for infectious diseases, with candidates such as PDS0201 for tuberculosis, PDS0202 as an investigational influenza vaccine, and PDS0203, a vaccine aimed at preventing COVID-19. The company has established strategic partnerships and licensing agreements with notable entities including the National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. PDS Biotechnology Corporation was founded in 2005 and is headquartered in Florham Park, New Jersey.
Day range
Current $1.02
52-week range
Current $1.02
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
28
Expensive
Sentiment
42
Mixed
Risk
77
High Risk
Momentum
25
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
PDS Biotechnology Corporation is a clinical-stage biopharmaceutical firm dedicated to advancing innovative, multi-functional immunotherapies to combat cancer. Its primary drug candidate, PDS0101 (HPV16), is currently undergoing Phase II clinical trials, positioned as an initial treatment option for recurrent or metastatic head and neck cancer, human papillomavirus (HPV)-associated malignancies, and cervical cancer. The company's developmental pipeline further includes several preclinical product candidates. These comprise PDS0102, utilizing T-cell receptor gamma alternate reading frame protein (TARP) for prostate and breast cancers; PDS0103 (MUC-1) targeting ovarian, colorectal, lung, and breast cancers; and PDS0104, which incorporates Tyrosinase-related protein 2 for the treatment of melanoma. Beyond oncology, PDS Biotechnology is also engaged in developing treatments for infectious diseases, with candidates such as PDS0201 for tuberculosis, PDS0202 as an investigational influenza vaccine, and PDS0203, a vaccine aimed at preventing COVID-19. The company has established strategic partnerships and licensing agreements with notable entities including the National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. PDS Biotechnology Corporation was founded in 2005 and is headquartered in Florham Park, New Jersey.
Day range
Current $1.02
52-week range
Current $1.02
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cost of goods sold | — | 59.79K USD | 57.33K USD | — | — |
| Gross profit | — | −59.79K USD | −57.33K USD | — | — |
| Research and development | 19.03M USD | 22.57M USD | 27.76M USD | 29.43M USD | 11.25M USD |
| Selling, general, and administrative | 12.52M USD | 13.7M USD | 15.28M USD | 12.24M USD | 10.18M USD |
| Operating expenses | 31.54M USD | 36.26M USD | 43.05M USD | 41.67M USD | 21.44M USD |
| Interest income | 1.22M USD | 2.52M USD | 2.9M USD | 935.18K USD | 4.35K USD |
| Interest expense | 5.34M USD | 4.67M USD | 4.21M USD | 1.32M USD | — |
| Depreciation and amortization | 21.84K USD | 21.11M USD | 57.33K USD | 86 USD | 5.36K USD |
| Operating income | −31.54M USD | −36.32M USD | −43.05M USD | −41.67M USD | −21.44M USD |
| Net income | −34.5M USD | −37.61M USD | −42.94M USD | −40.85M USD | −16.92M USD |
Company facts updated Oct 9, 2026.
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI
iShares Micro-Cap ETFIWC
Vanguard Extended Market ETFVXFAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
